Moreover, compared with glioma patients with nonmetastatic tumors, FAM87A was suppressed in patients with metastatic tumors (Figure 1(d)) and decreased markedly with the increase of pathological stage (Figure 1(e)). Here, FAM87A is linked to metastatic neoplasm.